Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted) (2020 - 2026)
Intellia Therapeutics (NTLA) reported EPS (Weighted Average and Diluted) of -$0.81 for Q1 2026, up 26.36% year-over-year from -$0.64 in Q1 2025, and up 1.22% quarter-over-quarter from -$0.82 in Q4 2025.
Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.81 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.81, up 26.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.53 (up 32.38% YoY), and the FY2025 annual result was -$3.81, up 27.43% from the prior year.
- EPS (Weighted Average and Diluted) rose to -$0.81 in Q1 2026 per NTLA's latest filing, from -$0.82 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.81 in Q1 2026 and troughed at -$1.96 in Q1 2022.
- A 5-year average of -$1.26 and a median of -$1.33 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) slumped 53.61% in 2022, then jumped 40.31% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.38 in 2022, then slipped by 5.8% to -$1.46 in 2023, then gained by 13.7% to -$1.26 in 2024, then surged by 34.92% to -$0.82 in 2025, then increased by 1.22% to -$0.81 in 2026.
- Business Quant data shows NTLA's EPS (Weighted Average and Diluted) at -$0.81 in Q1 2026, -$0.82 in Q4 2025, and -$0.92 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -0.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.81 |
| Dec 31, 2025 | -0.82 |
| Sep 30, 2025 | -0.92 |
| Jun 30, 2025 | -0.98 |
| Mar 31, 2025 | -1.10 |
| Dec 31, 2024 | -1.26 |
| Sep 30, 2024 | -1.34 |
| Jun 30, 2024 | -1.52 |
| Mar 31, 2024 | -1.12 |
| Dec 31, 2023 | -1.46 |
| Sep 30, 2023 | -1.38 |
| Jun 30, 2023 | -1.40 |
| Mar 31, 2023 | -1.17 |
| Dec 31, 2022 | -1.38 |
| Sep 30, 2022 | -1.49 |
| Jun 30, 2022 | -1.33 |
| Mar 31, 2022 | -1.96 |
| Dec 31, 2021 | -1.10 |
| Sep 30, 2021 | -0.97 |
| Jun 30, 2021 | -1.01 |